Contribution of the tissue angiotensin converting enzyme to the antihypertensive effect of altiopril calcium (MC-838) in spontaneously hypertensive rats.

Abstract	The effect of a new orally active angiotensin converting enzyme (ACE) inhibitor, calcium (-)-N-[(S)-3-[(N-cyclohexylcarbonyl-D-alanyl)thio]-2-methylpropionyl+ ++]-L- prolinate (MC-838, altiopril calcium), on systemic blood pressure (SBP) and tissue ACE activity has been examined in conscious spontaneously hypertensive rats (SHRs). MC-838 (3 mg kg-1) given orally to SHRs elicited a long-lasting hypotension lasting over 24 h. With the development of the hypotension, MC-838 significantly reduced ACE activity in the lung, kidney and aorta, but not in the brain and heart. Suppression of plasma ACE and rise of plasma renin activity occurred only transiently at an earlier stage.
Authors	K Kamei, Y Shiraki, T Koga, K Sakai
Journal	The Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 41 Issue 4 Pg. 279-80 (Apr 1989) ISSN: 0022-3573 [Print] England
PMID	2568474 (Publication Type: Journal Article)
Chemical References	Antihypertensive Agents MC 838 Proline Peptidyl-Dipeptidase A Renin
Topics	Animals Antihypertensive Agents (pharmacology) Hypertension (physiopathology) Male Peptidyl-Dipeptidase A (blood, metabolism, physiology) Proline (analogs & derivatives, pharmacology) Rats Rats, Inbred SHR Renin (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!